Mohd. Raja
Hindustan University
7 Papers
33 Citations
Mohd. Raja is an academic researcher from Hindustan University. The author has contributed to research in topics: Chemistry & Receptor tyrosine kinase. The author has an hindex of 5, co-authored 6 publications.
Chat about Author
Papers
Targeting prostate cancer with compounds possessing dual activity as androgen receptor antagonists and HDAC6 inhibitors.
Pradeep S. Jadhavar,Ramachandran Sreekanth A,Eduardo Riquelme,Ashu Gupta,Kevin P. Quinn,Devleena Shivakumar,Soumya S. Ray,Dnyaneshwar Zende,Anjan Kumar Nayak,Sandeep K. Miglani,Sathe Balaji Dashrath,Mohd. Raja,Olivia Farias,Iván E. Alfaro,Sebastian Belmar,Javier Sanchez Guerrero,Sebastian Bernales,Sarvajit Chakravarty,David T. Hung,Jeffrey N. Lindquist,Roopa Rai +20 more
TL;DR: The design, synthesis and biological evaluation of dual-acting compounds which target AR and are also specific towards HDAC6 are described, which led to compound 10 which was found to have potent dual activity.
18
Discovery of Pyrazolopyrimidine Derivatives as Novel Dual Inhibitors of BTK and PI3Kδ
Brahmam Pujala,Anil Agarwal,Sandip Middya,Monali Banerjee,Arjun Surya,Anjan Kumar Nayak,Ashu Gupta,Sweta Khare,Rambabu Guguloth,Nitin Atmaram Randive,Bharat Uttam Shinde,Anamika Thakur,Dhananjay I. Patel,Mohd. Raja,Michael J. Green,Jennifer Alfaro,Patricio Avila,Felipe Pérez de Arce,Ramona Almirez,Stacy Kanno,Sebastian Bernales,David T. Hung,Sarvajit Chakravarty,Emma McCullagh,Kevin P. Quinn,Roopa Rai,Son Minh Pham +26 more
TL;DR: A series of novel compounds that have low nanomolar potency against both BTK and PI3Kδ as well as acceptable PK properties that could be useful in the development of treatments against B-cell related diseases are reported.
Design, synthesis and optimization of bis-amide derivatives as CSF1R inhibitors
Ramachandran Sreekanth A,Pradeep S. Jadhavar,Sandeep K. Miglani,Manvendra Singh,Deepak P. Kalane,Anil Agarwal,Sathe Balaji Dashrath,Kakoli Mukherjee,Ashu Gupta,Srijan Haldar,Mohd. Raja,Siddhartha Singh,Son Minh Pham,Sarvajit Chakravarty,Kevin P. Quinn,Sebastian Belmar,Iván E. Alfaro,Christopher Higgs,Sebastian Bernales,Francisco J. Herrera,Roopa Rai +20 more
TL;DR: A lead optimization effort resulted in the identification of a potent, cellular active and orally bioavailable bis-amide CSF1R inhibitor, which led to improved metabolic stability and Caco2 permeability, which in turn resulted in good oral bioavailability in mice.
18
Temozolomide analogs with improved brain/plasma ratios - Exploring the possibility of enhancing the therapeutic index of temozolomide.
Roopa Rai,Monali Banerjee,Darren H. Wong,Emma McCullagh,Ashu Gupta,Shailendra Tripathi,Eduardo Riquelme,Ramnivas Jangir,Shyamraj Yadav,Mohd. Raja,Pankaj Melkani,Vikas Dixit,Umesh K. Patil,Ritesh Shrivastava,Sandip Middya,Felipe Olivares,Javier Sanchez Guerrero,Arjun Surya,Son Minh Pham,Sebastian Bernales,Andrew A. Protter,David T. Hung,Sarvajit Chakravarty +22 more
TL;DR: These compounds are imidazotetrazine analogs, expected to act through the same mechanism as temozolomide, and have the potential to improve efficacy and therapeutic index in the treatment of glioblastoma.
14
In Vivo Anticancer Evaluation of 6b, a Non-Covalent Imidazo[1,2-a]quinoxaline-Based Epidermal Growth Factor Receptor Inhibitor against Human Xenograft Tumor in Nude Mice
Zahid Rafiq Bhat,Manvendra Kumar,Nisha Sharma,Umesh Prasad Yadav,Tashvinder Singh,Gaurav Joshi,Brahmam Pujala,Mohd. Raja,Joydeep Chatterjee,Kulbhushan Tikoo,Sandeep Singh,Raj Kumar +11 more
TL;DR: The in vivo findings of the 6b compound were in corroboration with the in vitro results, suggesting that 6b possessed potential anticancer activity against EGFR-dependent lung cancer.